title: Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.
abstract: Deferiprone is an orally active iron-chelating agent used in the management of transfusion-related hemosiderosis. It has been in clinical use for over 20 years and has been shown to be effective in reducing cardiac iron load and improving cardiac function. As cardiac siderosis is the leading cause of death in patients with transfusion-dependent thalassemia, deferiprone helps to improve the overall prognosis of these patients. It is relatively well tolerated with gastrointestinal symptoms being the commonest side effects. Agranulocytosis (0.5%), neutropenia (9%), thrombocytopenia (up to 45%) and arthropathy (20%) are the most important side effects and may require discontinuation of therapy. Regular monitoring of blood counts is recommended for patients on deferiprone therapy.
authors.affiliation: Division of Genetics, 300 Longwood Avenue, Boston Children's Hospital, Boston, MA 02115, USA.
authors.forename: Saumya S
authors.initials: SS
authors.lastname: Jamuar
authors.forename: Angeline H M
authors.initials: AH
authors.lastname: Lai
keywords: deferiprone; iron chelation; iron overload; thalassemia